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We report the final 2-year end-of-study results from the first clinicaltrial investigating combination treatment with ruxolitinib andlow-dose pegylated interferon-α2 (PEG-IFNα2). The study includ-
ed 32 patients with polycythemia vera and 18 with primary or secondary
myelofibrosis; 46 patients were previously intolerant of or refractory to PEG-
IFNα2. The primary outcome was efficacy, based on hematologic parame-
ters, quality of life measurements, and JAK2 V617F allele burden. We used
the 2013 European LeukemiaNet and International Working Group-
Myeloproliferative Neoplasms Research and Treatment response criteria,
including response in symptoms, splenomegaly, peripheral blood counts,
and bone marrow. Of 32 patients with polycythemia vera, ten (31%)
achieved a remission which was a complete remission in three (9%) cases.
Of 18 patients with myelofibrosis, eight (44%) achieved a remission; five
(28%) were complete remissions. The cumulative incidence of peripheral
blood count remission was 0.85 and 0.75 for patients with polycythemia
vera and myelofibrosis, respectively. The Myeloproliferative Neoplasm
Symptom Assessment Form total symptom score decreased from 22 [95%
confidence interval (95% CI):, 16-29] at baseline to 15 (95% CI: 10-22) after
2 years. The median JAK2 V617F allele burden decreased from 47% (95%
CI: 33-61%) to 12% (95% CI: 6-22%), and 41% of patients achieved a
molecular response. The drop-out rate was 6% among patients with poly-
cythemia vera and 32% among those with myelofibrosis. Of 36 patients
previously intolerant of PEG-IFNα2, 31 (86%) completed the study, and 24
(67%) of these received PEG-IFNα2 throughout the study. In conclusion,
combination treatment improved cell counts, reduced bone marrow cellular-
ity and fibrosis, decreased JAK2 V617F burden, and reduced symptom bur-
den with acceptable toxicity in several patients with polycythemia vera or
myelofibrosis. #EudraCT2013-003295-12.
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ABSTRACT
Introduction
This is the first clinical trial investigating combination
treatment with ruxolitinib and pegylated interferon-a2
(PEG-IFNa2) for patients with chronic Philadelphia-nega-
tive myeloproliferative neoplasms. Hydroxyurea is the
most frequently used cytoreductive agent, but some
patients are intolerant of or resistant to this drug.1-3 PEG-
IFNa2 is another first-line treatment option, but its clin-
ical use is limited by toxicity.3-12 Ruxolitinib reduces symp-
tom burden in patients with polycythemia vera (PV) and
primary or secondary myelofibrosis (MF), but the clinical
benefit in patients with PV is still controversial.3,13-19
Ruxolitinib may increase the efficacy and tolerability of
PEG-IFNa2,20,21 and we have reported promising results
from a 1-year interim analysis, with an overall remission
rate of 9% in PV patients and 39% in MF patients.22
PEG-IFNa2 effectively normalizes blood cell counts and
may prevent disease-related thromboembolic complica-
tions in patients with essential thrombocythemia, PV, and
MF.4-8,10,11,23-26 Furthermore, an anti-clonal activity of PEG-
IFNa2 has been shown by reductions of the Januskinase-2
(JAK2) V617F allele burden and sustained deep molecular,
hematologic, and histological remission in some patients,
even several years after cessation of treatment.5,6,23,27-29
However, some patients do not respond adequately to
PEG-IFNa2, and treatment is limited by frequent toxicities
and high discontinuation rates, of 10–50%, due to adverse
events.5-8,10-12 In particular, inflammatory side effects such
as fever, flu-like symptoms, fatigue, and autoimmune thy-
roiditis are troublesome.5-7,10,11
JAK1-2 inhibitor treatment with ruxolitinib reduces dis-
ease-related symptoms and splenomegaly, and it may pro-
long survival in patients with MF.13,14,16,18,19 Furthermore,
ruxolitinib reduces elevated blood cell counts and symp-
tom burden in patients with PV.15,17 Inflammation is a crit-
ical element of myeloproliferative neoplasms, and the
effect of ruxolitinib seems to be mediated mainly by anti-
inflammatory mechanisms.20 Moreover, a reduction in the
JAK2 V617F allele burden has been observed.30 Adding
ruxolitinib to PEG-IFNa2 treatment may increase the effi-
cacy and tolerability of PEG-IFNa2 by reducing inflamma-
tion.21,22 Combination treatment may also have a synergis-
tic effect on the malignant clone, and reduced dosage of
both drugs may lead to fewer side-effects compared with
monotherapies.20 The rationales for the combination treat-
ment have previously been described in detail.21
We report the 2-year end-of-study results from the
phase II COMBI study assessing efficacy and safety of
combination treatment with ruxolitinib and PEG-IFNa2.
Methods
Study design
The COMBI study (#EudraCT2013-003295-12) was an investi-
gator-initiated, multicenter, open-label, single-arm phase II study;
we included 50 patients: 32 with PV and 18 with MF. The study
was conducted between 2014 and 2018 at three sites in Denmark
and approved by the Danish Regional Science Ethics Committee
and the Danish Medicines Agency. It was done under the prin-
ciples of the Declaration of Helsinki. Patients gave written
informed consent to their participation. For further details on the
methods, see the Online Supplementary Methods section.
Patients aged ≥18 years with a diagnosis of PV or MF according
to the 2008 World Health Organization criteria were considered
eligible, if they had evidence of active disease, defined as one or
more of the following: need for phlebotomy, white blood cell
count ≥10x09/L, platelet count ≥400x109/L, constitutional symp-
toms, pruritus, symptomatic splenomegaly, and previous throm-
bosis. Key exclusion criteria were: Eastern Cooperative Oncology
Group performance status ≥3, severe comorbidity, white blood
cell count <1.5x109/L, and platelet count <100x109/L.
Patients were initially treated with PEG-IFNa2a [Pegasys®;
Genentech (Roche), South San Francis-co, CA, USA] 45 μg/week
or PEG-IFNa2b (PegIntron®; Merck Sharp & Dohme,
Hertfordshire, UK) 35 μg/week subcutaneously and ruxolitinib
(Jakavi®; Novartis, Basel, Switzerland) 5-20 mg BID orally depend-
ing on platelet count.
Study visits included documentation of adverse events, full-
scale hematology, blood biochemistry investigations, determina-
tion of the Myeloproliferative Neoplasm Symptom Assessment
Form (MPN-SAF) score,31 and assessment of compliance by
research staff. Bone marrow biopsies were done at baseline and
after 1 and 2 years of treatment. Spleen size was measured as the
longest diameter by sonography. The proportions of JAK2 V617F
and CALR-mutated alleles were quantified using a high-sensitivity
real-time quantitative polymerase chain reaction method on
whole blood.32,33
Endpoints
The primary outcome was efficacy, based on hematologic
parameters, quality of life measurements, and the JAK2 V617F
burden. The 2013 European LeukemiaNet and International
Working Group-Myeloproliferative Neoplasms Research and
Treatment response criteria were used to assess efficacy.34,35
In brief, for patients with PV, a complete remission (CR)
required resolution of disease-related symptoms and
hepatosplenomegaly, peripheral blood count remission (PBCR), no
progression of the disease, no hemorrhagic or thrombotic events,
and bone marrow histological remission (BMHR). A partial remis-
sion (PR) required all the above except BMHR.
For patients with MF, a CR required resolution of disease-relat-
ed symptoms and hepatosplenomegaly, and PBCR. A PR required
resolution of disease-related symptoms and hepatosplenomegaly,
and either PBCR or BMHR. Clinical improvement was defined as
an anemia response or symptoms response. Progressive disease
was defined as significantly increased splenomegaly or leukemic
transformation.34,35
Molecular response (MR) was classified as either complete
(CMR), defined as eradication of a pre-existing abnormality, or
partial (PMR), defined as a ≥50% decrease in JAK2 V617F allele
burden from baseline in patients with a baseline allele burden
≥20%. 
Statistical analyses 
We did the statistical analyses using R.3.2.3. Response rates are
presented with descriptive statistics. All patients initiating the
study treatment were evaluated for response, similar to the modi-
fied intention-to-treat principle used for randomized, controlled
trials. Statistical analyses are described in the Online Supplementary
Methods section. P values <0.05 were considered statistically sig-
nificant.
Results
Patients’ characteristics
In total, we included 51 patients in the study, and 50
patients initiated combination treatment; 32 had PV, and
Ruxolitinib and interferon-a for PV and MF
haematologica | 2020; 105(9) 2263
19 had MF (Table 1). One patient with MF developed
acute myeloid leukemia and died shortly after inclusion,
before initiation of the combination treatment. The
patient was excluded from further analysis. The MF
patients were in an early stage of disease, with three
(17%) having intermediate-2 risk and none having high-
risk disease based on the Dynamic International
Prognostic Scoring System-Plus (DIPSS+) score. Notably,
47 (94%) of the patients had previously been treated with
PEG-IFNa2; 31 (66%) were intolerant, ten (21%) were
refractory, and six (13%) were both. Moreover, 27 (54%)
had been treated with hydroxyurea, and 25 (50%) had
been treated with both hydroxyurea and PEG-IFNa2. 
Response evaluations
Of 32 patients with PV, ten (31%) achieved a remission;
three (9%) achieved CR, and seven (22%) achieved PR
(Figure 1A). Three additional patients achieved BMHR
but did not fulfill the criteria for remission; one patient
had an increase in total symptom score (TSS); one patient
had elevated platelet count, and one patient had both.
One patient had progressive disease due to the devel-
opment of post-PV MF. Three PV patients dropped out
and were classified as having no response. One patient
chose not to have a bone marrow biopsy done after 2
years, and five patients had an unsuccessful biopsy. Two
of these were in PR.
Of 18 patients with MF, eight (44%) achieved remis-
sion; five (28%) achieved CR, and three (17%) achieved
PR. Moreover, two (12%) had clinical improvement, both
having symptoms response with a ≥50% reduction in
TSS (Figure 1A). One additional patient achieved BMHR
and PBCR but suffered from grade 1 fatigue and was
defined as having stable disease. Two patients had stable
disease. Five patients dropped out but did not have pro-
gressive disease.
Peripheral blood cell count remission
Of 32 PV patients, five fulfilled the criteria for PBCR at
baseline. For the 27 patients who did not have PBCR at
baseline, the median time to PBCR was 1 month, and the
cumulative incidence of PBCR after 2 years was 0.85
(Figure 1B). Of the five patients with PBCR at baseline,
four had PBCR at 2 years. The median duration of the
first PBCR was 14 months (Online Supplementary Figure
S1), but 12 of the 13 patients who lost PBCR achieved it
again during the study period. The proportion of PV
patients in PBCR during the study is shown in Figure 1C.
Of 14 PV patients in need of phlebotomies within 3
months before inclusion, four needed phlebotomies dur-
ing the trial, three of whom required just one phleboto-
my. Two additional patients required phlebotomies dur-
ing the trial.
Of 18 MF patients, three fulfilled the criteria for PBCR
at baseline. For the 15 patients who did not have PBCR at
baseline, the median time to PBCR was 3 months, and the
cumulative incidence of PBCR after 2 years was 0.73
(Figure 1B). Of the three patients with PBCR at baseline,
two had PBCR after 2 years. The median duration until
the first PBCR was 5 months (Online Supplementary Figure
S1), but seven of the eight patients who lost PBCR
achieved it again during the study period. The proportion
of MF patients in PBCR during the study is shown in
Figure 1D.
Hematocrit, white blood cell count, and platelet count
were all significantly reduced after 2 weeks, and throughout
the study period (Figure 1E-G); there were no significant
differences between patients with PV and those with MF.
Patient-reported quality-of-life outcomes
During the 2 years of treatment, we observed a statisti-
cally significant reduction in MPN-SAF TSS from baseline
at all time points except at 1 and 2 years (Figure 2A). The
median TSS was reduced from 22 [95% confidence inter-
val (95% CI): 16-29] at baseline to 15 (95% CI: 10-22)
after 2 years. Compared with patients not achieving
remission, patients in remission after 2 years had signifi-
cantly (P<0.05) larger reductions in TSS at several time
points (figure 2B). The median TSS in patients achieving
remission was reduced from 17 (95% CI: 10-27) at base-
line to 7 (95% CI: 4-13) after 2 years. The median TSS in
patients not achieving remission was 26 (95% CI: 18-37)
at baseline and 25 (95% CI: 16-36) after 2 years. The fol-
lowing items of the TSS were significantly reduced at
more than half of the time points, compared with base-
line: early satiety (P<0.05), night sweats (P<0.01), itching
(P<0.01) and weight loss (P<0.001) (Figure 2C). We found
no significant difference in TSS change between patients
with MF and patients with PV.
A.L. Sørensen et al.
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Table 1. Patients’ characteristics at baseline.
                                                                Polycythemia vera         Myelofibrosis
                                                                         (n=32)                       (n=18)
Age (years), median (IQR)                                  57 (49, 67)                      59 (51, 67)
Sex, male (%)                                                              19 (59)                            10 (56)
Post-ET or -PV myelofibrosis, n (%)                           -                                 5 (27.8)
Years since diagnosis, median (IQR)              6.9 (2.9, 10.0)                  6.2 (2.6, 8.0)
DIPSS+ score for myelofibrosis patients                                                            
Low, n (%)                                                                        -                                   6 (33)
Intermediate-1, n (%)                                                   -                                   9 (50)
Intermediate-2, n (%)                                                   -                                   3 (17)
High-risk PV, n (%)                                                     21 (66)                                  -
Prior thrombosis, n (%)                                            9 (28)                              2 (11)
Constitutional symptoms, n (%)                             16 (50)                             8 (44)
Need of phlebotomies in last 3 months, n (%)  14 (44)                              0 (0)
Prior cytoreductive treatment                                                                                 
PEG-IFNa2, n (%)                                                   30 (94)                            17 (94)
HU, n (%)                                                                   21 (66)                             6 (33)
PEG-IFNa2 and HU, n (%)                                    19 (59)                             6 (33)
Anagrelide, n (%)                                                      8 (25)                              5 (28)
JAK2 V617F positive, n (%)                                      32 (100)                           12 (67)
JAK2 V617F allele burden (%), median (IQR) 40 (19, 79)                      45 (23, 62)
Palpable spleen, n (%)                                               6 (19)                              3 (17)
Spleen size by US (cm), median (IQR)        14.0 (12.1, 17.3)              14.0 (12, 18.5)
MPN-SAF TSS, median (IQR)                           21.0 (5.5, 35.0)             24.0 (18.5–41.0)
Hemoglobin (g/dL), median (IQR)                13.3 (12.7, 13.9)            12.8 (12.0, 13.4)
Hematocrit, median (IQR)                               0.42 (0.41, 0.44)            0.40 (0.35, 0.41)
WBC count (x 109/L), median (IQR)                8.4 (5.4, 12.7)                 7.8 (5.4, 10.5)
Platelet count (x 109/L), median (IQR)          401 (251, 592)               419 (381, 464)
IQR: interquartile range; ET: essential thrombocythemia; PV: polycythemia vera; DIPSS+:
Dynamic International Prog-nostic Scoring System-Plus; PEG-IFNa2: pegylated interferon-a2;
HU, hydroxyurea; US: ultrasonography; MPN-SAF TSS, Myeloproliferative Neoplasm Symptom
Assessment Form total symptom score; WBC: white blood cell.
Spleen size
In nine patients, five with PV and four with MF, palpa-
ble splenomegaly was present at baseline. After 2 years,
four of these patients no longer had palpable
splenomegaly, two had reduced palpable splenomegaly,
one had increased palpable splenomegaly, and two had
discontinued treatment. In one of the two patients who
dropped out, palpable splenomegaly was reduced before
drop-out; in the other, it increased. Spleen size, measured
by sonography, was reduced during treatment (P<0.001)
(Online Supplementary Figure S2), and after 2 years of ther-
apy, spleen size was reduced by 10% (95% CI: 6-15%).
The reduction was statistically significant for PV patients
at all time points, but not for MF patients at 6 months and
subsequently (Online Supplementary Figure S2).
Molecular response
We observed statistically significant reductions in the
JAK2 V617F allele burden at all time points (P<0.001)
(Figure 3A). The median JAK2 V617F allele burden after 2
Ruxolitinib and interferon-a for PV and MF
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Figure 1. Response evaluations and peripheral blood cell remission. (A) Response evaluations after 2 years of treatment in patients with polycythemia vera (PV) or
myelofibrosis (MF). Responses are classified as complete remission (CR), partial remission (PR), no response (NR), progressive disease (PD), drop-outs (DO), and,
for MF patients, clinical improvement (CI) and stable disease (SD) (B) Kaplan-Meier plot depicting the cumulative incidence of peripheral blood count remission
(PBCR) in patients not in PBCR at baseline (n=42). (C, D) Distribution of participants in PBCR and the number of patients dropping out of the protocol, patients with
PV, and patients with MF. (E-G) Estimated change, with 95% confidence interval, in hematocrit (HCT) (E), white blood cell count (WBC) (F), and platelet count (PLT)
(G), using generalized linear mixed models.
A B
C D
E F G
years was 12% (95% CI: 6-22%) compared with 47%
(95% CI: 33-61%) at baseline. In 33 of 44 JAK2 V617F-
mutated patients, measurements of the JAK2 V617F allele
burden were available from within the year before inclu-
sion. There were no significant differences in the JAK2
V617F allele burden before inclusion compared with base-
line. Of the 44 patients with the JAK2 V617F mutation,
one (2%) achieved CMR, and 17 (39%) achieved PMR
within 2 years of treatment (Figure 2B). Setting the limit of
CMR at 1%, four (9%) patients achieved CMR, and 16
(36%) achieved PMR within 2 years of treatment (Online
Supplementary Figure S3). Further analyses were done with
a limit of CMR 1-5% (Online Supplementary Table S1). We
observed no difference in the JAK2 V617F allele burden
change between patients with PV and patients with MF
(Online Supplementary Figure S4). The JAK2 V617F allele
burden of patients who did not complete 2 years of treat-
ment (n=5) is shown in Online Supplementary Figure S5;
two of these patients had reductions in JAK2 V617F allele
burden. 
Of four patients with a CALR mutation, one had a
decrease in allele burden during treatment, two had an
increase, and one dropped out of the study before a sec-
ond measurement could be done (Online Supplementary
Figure S6).
Patients achieving remission after 2 years had a statisti-
cally significant greater reduction in JAK2 V617F allele bur-
den compared with patients not achieving remission
(Figure 2C). Of the 39 patients with the JAK2 V617F muta-
tion who completed the study, 15 had a MR and 24 did
not; 11 (73%) patients with a MR achieved remission,
while five (21%) without a MR achieved remission
A.L. Sørensen et al.
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Figure 2. Change in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total symptom score and individual symptoms. (A) Median total symptom
score (TSS) with 95% confidence interval (95% CI). (B) The median TSS with 95% CI in participants with remission after 2 years and participants without remission.
(C) Individual symptom scores during treatment. Significance is defined as a statistically significant reduction compared with baseline at more than half of the time
points. All analyses were done using generalized linear mixed models comparing baseline values with measurements during treatment. *P<0.05; **P<0.01;
***P<0.001
A B
C
(P=0.003). Likewise, 14 (93%) patients with a MR were in
PBCR, while 12 (50%) without MR were in PBCR
(P=0.014). Moreover, patients with a MR at 2 years had a
higher rate of PBCR (P=0.025) with a median time to
PBCR of 1 month, compared with 6 months for patients
without a MR (Figure 2D). 
Drop-out and toxicity
Of the 32 PV patients who initiated treatment, two (6%)
dropped out within 2 years. Of 18 MF patients, six (33%)
dropped out. In total, the drop-out rate was 16%. Three
patients had an inadequate response; four had adverse
events; among these, two had neuropsychiatric adverse
events, one had multiple infections and gastrointestinal
bleeding and requested to be taken off protocol (Online
Supplementary Table S2). Eight (25%) PV patients and one
(6%) MF patient discontinued PEG-IFNa2 treatment
while continuing treatment with ruxolitinib, and one PV
(3%) patient discontinued ruxolitinib treatment. In total,
17 (34%) patients, ten (31%) with PV and seven (39%)
with MF, discontinued PEG-IFNa2; ten (59%) of these due
to side-effects likely related to PEG-IFNa2 (Table 2). Of
the 50 patients, 32 (64%) had the dosage of ruxolitinib
reduced, and 35 (70%) had the dosage of PEG-IFNa2
reduced. 
The prevalence of adverse events, including disease-
related and study drug-unrelated events, observed in
≥10% of the patients and all grade 3 or 4 adverse events,
are presented in Table 2. Four thromboembolic events
occurred in three patients, two patients with PV and one
with MF: the events were myocardial infarction in one
patient, ischemic stroke in one patient, and both retinal
Ruxolitinib and interferon-a for PV and MF
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Figure 3. Change in JAK2-V617F allele burden and molecular response. (A) Median JAK2 V617F allele burden (JAK2) with 95% confidence interval (95% CI), using
a generalized linear mixed model to compare baseline with time points during treatment. (B) Waterfall plot over the best relative reduction in JAK2 with an indication
of complete molecular response (CMR), partial molecular response (PMR), and no molecular response (NMR) with baseline value below or above 20%. (C) Median
JAK2 and 95% CI in patients in partial or complete remission after 24 months and patients not in remission with stars representing a statistically significant differ-
ence in change from baseline between groups. (D) Cumulative incidence of peripheral blood cell remission (PBCR) in patients achieving a molecular response after
2 years and patients not achieving a molecular response. *P<0.05; **P<0.01; ***P<0.001
A B
C D
artery occlusion and multiple small pulmonary emboli in
one PV patient. Grade 1 or 2 hematologic adverse events,
and grade 3 anemia in patients with MF, were frequent.
We only recorded a few other grade 3 or 4 hematologic
adverse events. With regards to non-hematologic adverse
events, fatigue, influenza-like symptoms, pruritus, upper
airway infection, joint pain, muscle pain, and elevated lac-
tate dehydrogenase were observed in ≥30% of patients.
Six (12%) patients had grade 3 or 4 pneumonia, and one
(2%) had a grade 3 or 4 urinary tract infection. Two (4%)
patients had herpes zoster infection grade 1 or 2. In 11
(22%) patients, mood alterations, including depressive
symptoms, agitation, anxiety, and memory impairment,
were observed. No autoimmune thyroiditis occurred in
our study, but one patient was diagnosed with Sjögren
syndrome. All the drug-related adverse events are known
A.L. Sørensen et al.
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Table 2. Adverse events reported in ≥ 10% of patients and all grade 3 or 4 adverse events. 
                                                                                 Overall (n=50)                             Polycythemia vera (n=32)                          Myelofibrosis (n=18)
Drop-outs, n (%)                                                            8 (16%)                                                 2 (6%)                                                   6 (32%)
Total discontinuation of PEG-IFNa2, n (%)a                  17 (34%)                                             10 (31%)                                                7 (39%)
Adverse events                                              Grade 1–2,        Grade 3–4,                Grade 1–2,             Grade 3–4,              Grade 1–2,            Grade 3–4,
                                                                          N. (%)                N. (%)                        N. (%)                     N. (%)                      N. (%)                    N. (%)
Hematologic, n (%)
Anemia                                                                        38 (76.0)               7 (14.0)                         23 (71.9)                       1 (3.1)                        15 (83.3)                    6 (33.3)
Thrombocytopenia                                                   12 (24.0)                2 (4.0)                           9 (28.1)                        2 (6.2)                         3 (16.7)                      0 (0.0)
Leukopenia                                                                  22 (44)                  1 (2.0)                          15 (46.9)                       1 (3.1)                         7 (38.9)                      0 (0.0)
Non-hematologic, n (%)                                                                                                                                                                             
Cardiac ischemia                                                        0 (0.0)                   1 (2.0)                            0 (0.0)                         1 (3.1)                          0 (0.0)                       0 (0.0)
Palpitations                                                                 5 (10.0)                  0 (0.0)                            1 (5.6)                         0 (0.0)                         4 (12.5)                      0 (0.0)
Arterial hypertension                                                2 (4.0)                   3 (6.0)                            2 (6.2)                         3 (9.4)                          0 (0.0)                       0 (0.0)
Pulmonary embolism                                                 0 (0.0)                   1 (2.0)                            0 (0.0)                         1 (3.1)                          0 (0.0)                       0 (0.0)
Fatigue                                                                        23 (46.0)                1 (2.0)                          15 (46.9)                       0 (0.0)                         8 (44.4)                      1 (5.6)
Night sweats                                                              14 (28.0)                0 (0.0)                          10 (31.2)                       0 (0.0)                         4 (22.2)                      0 (0.0)
Influenza-like symptomsb                                       15 (30.0)                0 (0.0)                          11 (34.4)                       0 (0.0)                         4 (22.2)                      0 (0.0)
Fever                                                                             9 (18.0)                  0 (0.0)                           6 (18.8)                        0 (0.0)                         3 (16.7)                      0 (0.0)
Pruritus                                                                       20 (40.0)                0 (0.0)                          17 (53.1)                       0 (0.0)                         3 (16.7)                      0 (0.0)
Local injection site reactionsb                               10 (20.0)                0 (0.0)                           6 (18.8)                        0 (0.0)                         4 (22.2)                      0 (0.0)
Dyspepsia                                                                    6 (12.0)                  0 (0.0)                            3 (9.4)                         0 (0.0)                         3 (16.7)                      0 (0.0)
Nausea                                                                        14 (28.0)                0 (0.0)                           9 (28.1)                        0 (0.0)                         5 (27.8)                      0 (0.0)
Abdominal pain                                                          6 (12.0)                  0 (0.0)                            3 (9.4)                         0 (0.0)                         3 (16.7)                      0 (0.0)
Gastrointestinal bleedingc                                        0 (0.0)                   3 (6.0)                            0 (0.0)                         0 (0.0)                          0 (0.0)                      3 (16.7)
Upper airway infection                                            23 (46.0)                0 (0.0)                          15 (46.9)                       0 (0.0)                         8 (44.4)                      0 (0.0)
Pneumonia                                                                   3 (6.0)                  6 (12.0)                           3 (9.4)                        5 (15.6)                         0 (0.0)                       1 (5.6)
Urinary tract infection                                               4 (8.0)                   1 (2.0)                            2 (6.2)                         0 (0.0)                         2 (11.1)                      1 (5.6)
Weight gain                                                                  7 (14.0)                  0 (0.0)                           5 (15.6)                        0 (0.0)                         2 (11.1)                      0 (0.0)
Joint pain                                                                    19 (38.0)                  2 (4)                            14 (43.8)                       2 (6.2)                         5 (27.8)                      0 (0.0)
Muscle pain                                                                21 (42.0)                1 (2.0)                          16 (50.0)                       1 (3.1)                         5 (27.8)                      0 (0.0)
Mood alterationd                                                       11 (22.0)                0 (0.0)                           8 (25.0)                        0 (0.0)                         3 (16.7)                      0 (0.0)
Neuropathy: sensory                                                12 (24.0)                0 (0.0)                           7 (21.9)                        0 (0.0)                         5 (27.8)                      0 (0.0)
Dizziness                                                                     11 (22.0)                0 (0.0)                           6 (18.8)                        0 (0.0)                         5 (27.8)                      0 (0.0)
CNS ischemiae                                                             0 (0.0)                   2 (3.8)                            0 (0.0)                         1 (3.1)                          0 (0.0)                       1 (5.6)
Syncope                                                                         0 (0.0)                   1 (2.0)                            0 (0.0)                         1 (3.1)                          0 (0.0)                       0 (0.0)
Headache                                                                    12 (24.0)                0 (0.0)                           7 (21.9)                        0 (0.0)                         5 (27.8)                      0 (0.0)
Dyspnea                                                                       8 (16.0)                  0 (0.0)                           5 (15.6)                        0 (0.0)                         3 (16.7)                      0 (0.0)
Acute renal failure                                                     0 (0.0)                   1 (2.0)                            0 (0.0)                         1 (3.1)                          0 (0.0)                       0 (0.0)
Proteinuria                                                                   0 (0.0)                   1 (2.0)                            0 (0.0)                         1 (3.1)                          0 (0.0)                       0 (0.0)
Benign bladder tumor                                               0 (0.0)                   1 (2.0)                            0 (0.0)                         1 (3.1)                          0 (0.0)                       0 (0.0)
Elevated alanine transaminase                              7 (14.0)                  0 (0.0)                           6 (18.8)                        0 (0.0)                          1 (5.3)                       0 (0.0)
Elevated lactate dehydrogenase                           17 (34.0)                0 (0.0)                          12 (37.5)                       0 (0.0)                         5 (26.3)                      0 (0.0)
Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). aThe total number includes patients who
dropped out of the study. bRelated to pegylated interferon-a2 treatment. cOne patient had esophageal varices with bleeding, one had Mallory Weiss lesions, and one had rectal
bleeding. dFive patients had depressive symptoms, three experienced agitation, two anxiety, and two had memory impairment while one had both anxiety and memory impair-
ment. eOne patient had an ischemic stroke and a retinal artery occlusion. PEG-IFNa2: peglylated interferon-a2; CNS: central nervous system
toxicities of either ruxolitinib or PEG-IFNa2. The drug
doses and adverse events over time are shown in Figure 4.
The highest number of adverse events was observed with-
in the first 3 months of treatment.
Subgroup analyses
Of 32 PV patients who initiated treatment, 20 complet-
ed the study per protocol. Of these 20 patients, ten (50%)
achieved remission; three (15%) had CR, and seven (35%)
had PR. Eight of the 20 patients (40%) had a MR. At 2
years, 16 (80%) were in PBCR. Of the 18 MF patients who
initiated treatment, 12 completed the study per protocol.
Of these 12 patients, eight (67%) achieved remission; five
(42%) had CR, three (25%) had PR. Two (13%) had a clin-
ical improvement. Six patients (50%) had a MR, and nine
(75%) were in PBCR. 
Eight patients with the JAK2 V617F mutation discontin-
ued PEG-IFNa2 and continued ruxolitinib as monothera-
py. Their JAK2 V617F allele burdens are shown in Online
Supplementary Figure S7. Of these patients, three had
PBCR, and none had remission at 24 months. Three
achieved MR; however, two of these continued PEG-
IFNa2 until 15 and 21 months.
We stratified the main results based on the reason for
the prior discontinuation of PEG-IFNa2 (Online
Supplementary Table S3). Patients who were previously
intolerant of PEG-IFNa2 or naïve to this treatment had
more substantial reductions in the JAK2 V617F allele bur-
den compared with patients previously refractory to PEG-
IFNa2 treatment (mean reductions 61%, 65%, and 34%,
respectively). None of the three PEG-IFNa2-naïve patients
dropped out or discontinued PEG-IFNa2 treatment, and
two achieved remission and MR. We observed no other
notable differences.
Discussion
In this study, we showed that a novel combination of
ruxolitinib and low-dose PEG-IFNa2 is an effective treat-
ment with acceptable toxicity for patients with PV or MF.
We observed remission rates of 31% for patients with PV
and 44% for patients with MF. Moreover, both groups had
relatively high rates of sustained PBCR. Furthermore, we
found statistically significant reductions in the MPN-SAF
TSS, spleen size, and JAK2 V617F allele burden. The drop-
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Figure 4. Adverse events and drug
doses in patients with polycythemia
vera (left) and myelofibrosis (right).
The number of adverse events per
patient during the study period with
mean doses of pegylated interferon-
a2 (PEG-IFNa2) and ruxolitinib
(RUX). Gr. 1-2 non-hem AEs: grade 1-
2 non-hematologic adverse events;
gr. 3-4 non-hem AEs: grade 3-4 non-
hematologic adverse events; All gr.
hem AEs: All grade hematologic
adverse events.
out rate was comparable with that in previous studies of
PEG-IFNa2 in interferon-naïve patients.4-8,10,11 The prelimi-
nary results from the phase  I/II RUXOPEG study
(ClinicalTrials.gov NCT02742324) in patients with more
advanced MF support our findings.36 In that study, a
decrease in spleen size, improvement in blood counts, and
a reduction in JAK2 V617F allele burden were observed in
ten evaluable patients.
In total, 19% of PV patients and 33% of MF patients ful-
filled the criteria for BMHR. These findings suggest a dis-
ease-modifying effect of the combination treatment.34,35
Profound effects of PEG-IFNa2 on bone marrow histology
have been observed before, but usually after longer peri-
ods of treatment.28,29,37,38 Long-term treatment with ruxoli-
tinib in patients with MF seems to decrease bone marrow
fibrosis in only a small subset of patients.39 In a study
investigating PEG-IFNa2 treatment in 30 patients with
low- or intermediate-1 risk MF, two (7%) had CR, nine
(30%) had PR, and four (13%) had clinical improvement
after a median of 80.3 months.37 In our study, 28%, 17%,
and 12% of MF patients achieved CR, PR, and clinical
improvement, respectively, within 2 years.
Normalization of blood cell counts may be critical in
reducing the risk of thrombosis and improving sur-
vival.1,40,41 Therefore, a key finding of this study is the fast
and sustained normalization of elevated blood cell counts.
Similar high rates of hematologic response were observed
previously with a starting dose of PEG-IFNa2 90 µg/week
in patients with PV.5-7 In two phase II studies on PV
patients, the median time to complete hematologic
response was 2 and 3 months, respectively.5,6 In our study,
the median time to PBCR was 1 month for PV patients.
Similar to our study, most patients in one of those studies
had received previous cytoreductive treatment.6 In the
phase II study of ropeginterferon-a2b for PV patients, the
median time to complete hematologic resposne was more
than 1 year.42 Notably, baseline cell counts were higher in
these studies than in ours, and fewer patients had received
cytoreductive treatment before inclusion in two of the
studies, which may explain the shorter time to response
for PV patients in our study. Importantly, the response cri-
teria are not identical in the studies, and comparisons
between the studies should, therefore, be interpreted with
caution. Ropeginterferon-a2b induced higher rates of
blood cell count and spleen responses than did hydroxy -
urea after 2 years in an ongoing randomized controlled
trial.43 Ruxolitinib monotherapy in patients with PV previ-
ously treated with hydroxyurea, in the RESPONSE I and II
studies, resulted in PBCR rates of only 24% and 17% after
6 months.15,17 In comparison, 80% of PV patients in our
study achieved PBCR within 6 months. 
The MPN-SAF TSS decreased significantly during com-
bination treatment. Ruxolitinib has previously been
shown to reduce symptom burden in patients with MF or
PV with relatively few side-effects.14,15,17,19 In contrast, in a
study comparing hydroxyurea with PEG-IFNa2, no reduc-
tion in TSS was observed in either group.44
The marked reduction in the JAK2 V617F allele burden
and a 41% MR rate add further evidence of a selective
effect of combination treatment on the malignant clone.
Similar findings were made in patients treated with PEG-
IFNa2, and in the RESPONSE I study in which 34%
achieved MR after a median of 25 months of ruxolitinib
treatment.5,6,23,30 Notably, the baseline median JAK2 V617F
allele burden was 83% in the RESPONSE I study com-
pared with 47% in our study. It is likely that a higher pro-
portion of patients in RESPONSE I was evaluable for PMR
than in our study. Ruxolitinib treatment in patients with
MF has resulted in markedly lower rates of MR.45
Importantly, most previous studies assessing the JAK2
V617F allele burden have a limit of detection of
≥1%.5,6.30,42,45 The assay used in our study has a sensitivity
of ≤0.1% mutated alleles; this is important for compar-
isons of CMR and the total rate of MR. 
We found an association between MR and both remis-
sion and PBCR. Similarly, during ropeginterferon-a2b
treatment, an association between MR and hematologic
response was observed.42,43 Likewise, in a phase II study of
PEG-IFNa2, 94% of patients with MR also had a hemato-
logic response, and ten of 13 patients with complete bone
marrow response, also achieved MR; seven had CMR.11,29
The clinical benefit of MR is still unclear, but higher JAK2
V617F allele burden may be associated with a higher risk
of thrombotic events and progression to MF.41,46
The drop-out rate in our study was 16%; 8% stopped
due to adverse events. Notably, the drop-out rate was 6%
in PV patients and 32% in MF patients, respectively. In
total, 31% of PV patients and 37% of MF patients discon-
tinued PEG-IFNa2 when including patients who contin-
ued ruxolitinib monotherapy and drop-outs. This propor-
tion was similar in the two groups. Similar rates were
reported in previous studies on PEG-IFNa2 treatment.4-
8,10,11 However, in our study, 94% had previously been
treated with PEG-IFNa2; we therefore expected a high
rate of PEG-IFNa2 discontinuation. Moreover, in an ongo-
ing Danish study, the rate of PEG-IFNa2 discontinuation
in treatment-naïve patients was approximately 50%.12
Consequently, our findings are still very encouraging.
Ruxolitinib has been shown to increase the risk of infec-
tions, particularly in patients with MF.13,15,17,19,47 We
observed a relatively high infection rate, with six patients
(12%) developing grade 3 pneumonia. Importantly,
patients with fever were hospitalized and treated with
intravenous antibiotics, immediately for safety precau-
tions, and thereby fulfilled the criteria for grade 3 or 4
adverse events. This may have led to an overestimation of
grade 3 or 4 infectious adverse events. Indeed, only three
of the six grade 3 or 4 cases of pneumonia registered were
radiologically or microbiologically verified. Grade 1 or 2
anemia was recorded in 71.9% of PV patients. A high ini-
tial dose of ruxolitinib may account for this. The initial
ruxolitinib dose used in this study was 20 mg BID for
most patients compared with 10 mg BID in the
RESPONSE studies, since the phase II study dose-finding
study was published after preparation of the protocol.15,17
Accordingly, dosage reduction was frequent.
The inclusion criteria used in this trial do not directly
reflect the European LeukemiaNet guidelines for the initi-
ation of cytoreductive treatment.3 Indeed, both high- and
low-risk PV patients were included. This is similar to other
clinical trials investigating PEG-IFNa2 treatment.5,6,42 The
indications for administering PEG-IFNa2 are wider in
Denmark than internationally, and a strategy of an early
intervention targeting the malignant clone has previously
been described.48 Indeed, combination treatment as an
early intervention may induce deep clinical, histological
and molecular remission more frequently than PEG-IFNa2
monotherapy.5,6,23,27-29 Achieving deep remission could lead
to periods of observation without treatment or mainte-
nance treatment with a low dose of PEG-IFNa2, which
A.L. Sørensen et al.
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could greatly improve the quality of life of patients with
myeloproliferative neoplasms. Moreover, the risk of
thrombosis is greatest shortly after diagnosis, and aggres-
sive initial treatment may reduce the risk of early throm-
bosis.49 To this end, a new phase II study investigating
combination therapy in newly diagnosed PV patients has
been initiated (#EudraCT2018-0041-50).
One strength of our study is the investigation of bone
marrow remissions, which is essential in assessing a pos-
sible disease-modifying effect of new treatments.34,35
Additionally, we used the validated MPN-SAF question-
naire to assess the symptom burden during the treatment.
In patients with myeloproliferative neoplasms, in whom
it is essential to balance the efficacy of a treatment with
its toxicity, quality of life is a clinically relevant end-
point.34,35 Furthermore, we used a highly sensitive method
to assess the JAK2 V617F allele burden.32 A limitation of
our study is the relatively small population of MF
patients. Accordingly, results in this group should be
interpreted with caution. Moreover, the study lacked a
dose-finding phase I part, which would have been rele-
vant. Furthermore, the study was planned for 2 years of
treatment, but hematologic and histological responses
have been observed after several years of PEG-IFNa treat-
ment, and the response after 2 years may underestimate
the long-term clinical effect.28,29,37,38 Most patients on com-
bination treatment at the end of the study continued
treatment and post-hoc analyses with longer follow-up
are being planned to assess the long-term response to
combination treatment.
In conclusion, combination treatment with ruxolitinib
and low-dose PEG-IFNa2 improved peripheral blood cell
counts, bone marrow cellularity and fibrosis along with
symptom burden with acceptable toxicity in some
patients with PV and proliferative MF. Most patients in the
study were intolerant of or refractory to standard PEG-
IFNa2 treatment, and more than half had discontinued
previous treatment with hydroxyurea, highlighting that
this combination treatment is a viable choice for patients
with few treatment options left. 
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